Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
allergan
7
×
biotech
boston blog main
7
×
fda
7
×
life sciences
national blog main
national top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
eli lilly
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
ipo
amgen
bristol-myers squibb
cancer
europe blog main
europe top stories
glaxosmithkline
novartis
What
bio
roundup
drugs
fda
won
black
companies
days
diamond’s
drug
notes
acquisitions
airport
alkermes
announced
annual
antipsychotic
apocalypse
appetite
approval
arguments
august
beds
benefits
big
biotech
bread
busy
butter
buyout
cancer
cash
caveats
celgene
ceo
class
collabs
commercialized
commonly
competitors
Language
unset
Current search:
allergan
×
fda
×
" boston blog main "
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More